A communication from the Executive Office of Health and Human Services (see item 4000-0300 of Section 2 of Chapter 9 of the Acts of 2025) submitting a report on MassHealth pharmaceutical spending and utilization for fiscal years 2025 and 2026

This bill is a procedural communication from the Executive Office of Health and Human Services to the Massachusetts legislature, submitting a required report on MassHealth pharmaceutical spending and utilization for fiscal years 2025 and 2026. The report details that the program spent $3.01 billion on drugs in FY2025 before rebates and estimates spending of $3.36 billion for FY2026, with growth driven by increased use of high-cost medications. It highlights that direct negotiations with manufacturers have resulted in approximately $650 million in annual rebate value across 97 active drug contracts, while maintaining full access to FDA-approved drugs for program members. The submission fulfills a legislative mandate to provide transparency on how these financial mechanisms and new drug additions impact the overall MassHealth budget.